Skip to main content

Wound Management Technologies Showcases CellerateRX(R) Surgical and HemaQuell(TM) Resorbable Bone Wax at the American Academy of Orthopaedic Surgeons 2016 Annual Meeting

ADDISON, TX / ACCESSWIRE / March 1, 2016 / Wound Management Technologies, Inc. (OTCQB: WNDM) ("Company"), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, today announced that its subsidiary, Wound Care Innovations ("WCI"), will be an exhibitor at the American Academy of Orthopaedic Surgeons ("AAOS") Annual Meeting on March 2-4, to be held at the Orange County Convention Center in Orlando, Florida. Wound Care Innovations will be located at booth #805.

WCI will feature CellerateRX® Surgical and the benefits of Activated Collagen® on surgical wounds. CellerateRX Surgical has been used over 7,000 times in a wide variety of surgical cases including, orthopaedic, trauma, neurologic, vascular, foot and ankle, colorectal, OBGYN and general surgery since its introduction in 2012. The company will also showcase the newly FDA-cleared HemaQuell™ Resorbable Bone Wax from sister subsidiary Resorbable Orthopedic Products, LLC. HemaQuell is a water soluble material that is used as a tamponade to control bleeding from bone surfaces. HemaQuell is delivered in a unique applicator that allows surgeons to directly apply the waxy product on bleeding bones. Unlike other "bone wax" hemostats which can interfere with bone healing, the HemaQuell bone hemostasis material is completely resorbed between 2 and 7 days and does not delay bone healing.

Deborah Hutchinson, President, commented, "Our sales team is pleased to return to the American Academy of Orthopaedic Surgeons annual meeting as an exhibitor. The results from our clinical case studies featuring CellerateRX® Activated Collagen® on surgical wounds are increasingly impactful and we look forward to showcasing them to the largest gathering of orthopaedic surgeons." She continued, "Last year we generated a lot of interest in our development of a resorbable bone wax product and this year we look forward to introducing HemaQuell Resorbable Bone Wax."

About Wound Management Technologies

Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its Wound Care Innovations subsidiary's unique, patented collagen product line, CellerateRX(R) which is FDA-cleared for all wound types except 3rd degree burns. The Resorbable Orthopedic Products subsidiary owns a multi-faceted bone wax and bone void filler patent and markets products in the $1.5B biomaterials market and is anticipating new revenues from HemaQuell Resorbable Bone Wax. For more information visit www.wmgtech.com, www.celleraterx.com, www.crxsurgical.com and www.hemaquell.com.

Information about Forward-Looking Statements

The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the Company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Investor Contacts:

Investor Relations
972.218.0935
info@wmgtech.com

SOURCE: Wound Management Technologies

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.